Related Experiment Video

Updated: Dec 31, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Dual-target kinase drug design: Current strategies and future directions in cancer therapy

Dejuan Sun1, Yuqian Zhao1, Shouyue Zhang1

  • 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.

European Journal of Medicinal Chemistry
|January 14, 2020
PubMed

Insights

Targeting two protein kinases simultaneously offers a promising strategy to overcome cancer drug resistance. This review explores dual-target kinase drug design, including medicinal chemistry and computational methods, for improved cancer therapeutics.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacology and Drug Discovery
  • Oncology

Background:

  • Protein kinases regulate crucial cellular processes like proliferation and survival.
  • Dysregulation of protein kinases is implicated in cancer development and progression.
  • Current small-molecule kinase inhibitors face challenges with resistance mechanisms.

Purpose of the Study:

  • To review current strategies for designing dual-target kinase drugs.
  • To explore medicinal chemistry and computational approaches for dual-target drug development.
  • To provide insights into future directions for dual-target kinase inhibitors in cancer therapy.

Main Methods:

  • Review of existing literature on kinase inhibitors and drug resistance.
  • Analysis of medicinal chemistry strategies for dual-target drug design.
  • Evaluation of computational approaches in developing dual-target kinase drugs.

Main Results:

  • Dual-target kinase inhibition presents a strategy to enhance anti-tumor efficacy.
  • Simultaneous targeting of two kinases may overcome acquired resistance to single-target drugs.
  • Integration of medicinal chemistry and computational methods is key for effective dual-target drug design.

Conclusions:

  • Dual-target kinase drug design is a promising avenue for novel cancer therapeutics.
  • These strategies can potentially improve treatment outcomes and circumvent resistance.
  • Further research into dual-target kinase inhibitors is warranted for advancing cancer treatment.
Keywords:
Cancer therapyComputational drug designDual-target kinase drug designMedicinal chemistry designProtein kinases

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K